fda compounding semaglutide crackdown 2025 news The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the FDA ignites new fight over

The TGA says the eye disorder non-arteritic anterior ischaemic optic neuropathy (NAION) may result in permanent visual impairment and no treatment has been shown to improve visual acuity outcomes after the condition develops

This is one of the most comprehensive programs Ive reviewed

Concurrently, the glucose-lowering strategy has evolved from solely managing hyperglycemia to emphasizing comprehensive, long-term patient benefits

You can read more about how long semaglutide takes to suppress appetite in our detailed timeline guide

Yes, similar digestive effects may occur with other GLP-1 medications because they work through related pathways that influence appetite and digestion

This schedule is anecdotal and was not tested in the published human trials